<DOC>
	<DOC>NCT02043912</DOC>
	<brief_summary>In this epidemiological point prevalence study, medication profiles of patients with haloperidol treatment will be checked for drug interactions with risk of QT-prolongation. Additional clinical risk factors for developing QT-prolongation and safety measurements will be documented.</brief_summary>
	<brief_title>Drug Interactions With Risk of QT-prolongation in a General Hospital</brief_title>
	<detailed_description>Study design: epidemiological point prevalence study Target population: Patients with haloperidol treatment The following aspects will be investigated: - The medication profiles will be checked for drug interactions with risk of QT-prolongation. - Clinical risk factors for developing QT-prolongation (gender, age, (history of) cardiovascular disease, comorbidity,...) and lab results will be collected. - Safety measurements (e.g. ECG) will be documented.</detailed_description>
	<mesh_term>Long QT Syndrome</mesh_term>
	<mesh_term>Haloperidol</mesh_term>
	<mesh_term>Haloperidol decanoate</mesh_term>
	<criteria>treatment with haloperidol (started in the hospital) age &lt; 18 years</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2014</verification_date>
	<keyword>QT-prolongation</keyword>
	<keyword>Torsade de Pointes</keyword>
	<keyword>Haloperidol</keyword>
	<keyword>Drug interactions</keyword>
</DOC>